Volume | 153,303 |
|
|||||
News | (1) | ||||||
Day High | 3.34 | Low High |
|||||
Day Low | 3.105 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ARCA Biopharma Inc | ABIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.29 | 3.105 | 3.34 | 3.34 | 3.22 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
393 | 153,303 | $ 3.21 | $ 491,496 | - | 1.56 - 4.49 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:01:31 | 5 | $ 3.37 | USD |
ARCA Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
23.93M | 14.50M | - | 0 | -5.34M | -0.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ARCA Biopharma News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.20 | 3.42 | 3.105 | 3.30 | 23,620 | 0.14 | 4.37% |
1 Month | 3.25 | 4.07 | 2.9001 | 3.44 | 59,133 | 0.09 | 2.77% |
3 Months | 1.72 | 4.49 | 1.69 | 3.25 | 1,579,170 | 1.62 | 94.19% |
6 Months | 1.75 | 4.49 | 1.56 | 3.22 | 748,239 | 1.59 | 90.86% |
1 Year | 2.08 | 4.49 | 1.56 | 3.18 | 383,393 | 1.26 | 60.58% |
3 Years | 3.64 | 4.49 | 1.56 | 2.95 | 220,669 | -0.30 | -8.24% |
5 Years | 6.43 | 22.00 | 1.56 | 6.95 | 361,514 | -3.09 | -48.06% |
ARCA Biopharma Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |